52829-70-6 Usage
Uses
Used in Organic Synthesis:
5-Methyl-2-(2-nitrophenyl)oxazole is utilized as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its unique structure allows for versatile reactions, contributing to the development of new chemical entities.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-Methyl-2-(2-nitrophenyl)oxazole is employed as a starting material or a building block in the design and synthesis of new drugs. Its potential biological activity makes it a valuable candidate for drug discovery, particularly in exploring novel therapeutic agents.
Used in Biological Process Studies:
5-Methyl-2-(2-nitrophenyl)oxazole is also used as a research tool in the study of various biological processes. Its incorporation into biological systems can help researchers understand its interactions with biomolecules and its effects on cellular functions, potentially leading to insights into disease mechanisms and therapeutic targets.
Check Digit Verification of cas no
The CAS Registry Mumber 52829-70-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,8,2 and 9 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 52829-70:
(7*5)+(6*2)+(5*8)+(4*2)+(3*9)+(2*7)+(1*0)=136
136 % 10 = 6
So 52829-70-6 is a valid CAS Registry Number.
52829-70-6Relevant academic research and scientific papers
AMIDE DERIVATIVES AS SIRTUIN MODULATORS
-
Page/Page column 158, (2009/06/27)
Provided herein are novel sirtuin-modulating compounds represented by Structural Formula (I) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.
